|
S100A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
7.22650050910545E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62625468647093E-12 |
| Stage1-vs-Stage2 |
3.631800E-02 |
| Stage1-vs-Stage3 |
4.555700E-03 |
| Stage1-vs-Stage4 |
2.276500E-03 |
| Stage2-vs-Stage3 |
7.96419999999909E-05 |
| Stage2-vs-Stage4 |
5.65189999999216E-05 |
| Stage3-vs-Stage4 |
3.299000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.42290000004763E-06 |
| Normal-vs-Asian |
7.72939490190083E-11 |
| Caucasian-vs-AfricanAmerican |
1.969150E-01 |
| Caucasian-vs-Asian |
2.998800E-01 |
| AfricanAmerican-vs-Asian |
9.853600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
5.883900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
9.627400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.291800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.108200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.337000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.207200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.967800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.500600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.821700E-04 |
| Classical-VS-Follicular |
6.04749999999488E-05 |
| Classical-VS-Other |
6.537000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.68970004654767E-09 |
| Tall-VS-Other |
2.576200E-02 |
| Tall-VS-Normal |
1.63136171238421E-12 |
| Follicular-VS-Other |
3.976200E-01 |
| Follicular-VS-Normal |
<1E-12 |
| Other-VS-Normal |
8.196200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
5.423100E-04 |
|
|
